Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 58, Issue 17, Pages 6747-6752Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.5b00902
Keywords
-
Categories
Ask authors/readers for more resources
Herein we describe the optimization of a series of PDE4 inhibitors, with special focus on solubility and pharamcokinetics, to clinical compound 2, 4-(8-(3-fluorophenyl)-1,7-naphthyridin-6-yl)transcyclohexanecarboxylic acid. Although compound 2 produces emesis in humans when given as a single dose, its exemplary pharmacokinetic properties enabled a novel dosing regime comprising multiple escalating doses and the resultant achievement of high plasma drug levels without associated nausea or emesis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available